ClinicalTrials.gg
CompletedNCT00179621Updated Apr 14, 2011Results posted

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

A Phase 3 interventional study of Lenalidomide 5 mg and Lenalidomide 10 mg in Myelodysplastic Syndromes, sponsored by Celgene Corporation. Completed at 38 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-14.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies testing lenalidomide in Myelodysplastic Syndromes — none open to participants now, none under way, none of them phase 3. Lenalidomide · Myelodysplastic Syndromes.

Enrollment
3rd of 43
205 · median 32
Started
2005
with 2 others
Phase 3
3 of 44
none open now
Registered
4th of 44
by date
Lead sponsor
3 of 44
Celgene Corporation

Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, this one is the 3rd largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2005, is one of 3 in phase 3, and was the 4th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 323 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

None of the 44 studies testing lenalidomide in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing lenalidomide in Myelodysplastic Syndromes as a file.
02

Study summary

The purpose of this study was to compare 2 doses (10 mg and 5 mg) of lenalidomide to that of placebo in subjects with red blood cell (RBC) transfusion-dependent low- or intermediate-1-risk IPSS MDS associated with a deletion (del) 5q[31] cytogenetic abnormality. Study participants were randomized to one of the two treatment groups or to placebo and took the study drug for 16 weeks. At this timepoint, participants were evaluated for erythroid response. If participants did not achieve at least a minor erythroid response, they were discontinued from the Double-Blind phase and entered into the Open-Label phase. All erythroid responders at Week 16 were to continue in the Double-Blind phase for up to 52 weeks. For participants that were still responding at the end of Double-Blind phase, they could then rollover into the Open-Label phase for an additional two years. Participants could remain on study for up to a total of 3 years. All participants who discontinued from the study were followed every 4 months for overall survival and progression to acute myeloid leukemia (AML).

Read the detailed description

MDS-004 was a multicenter, randomized, double-blind, placebo-controlled, 3-arm study of 2 doses of lenalidomide versus placebo administered to RBC transfusion-dependent adults with low- or intermediate-1 risk MDS associated with a del 5q[31] cytogentetic abnormality. Potential participants that had a del 5q[31] cytogenetic abnormality plus other additional cytogenetic abnormalities were also eligible for enrollment. Transfusion-dependent anemia was defined as documentation that a participant with anemia due to MDS did not have any consecutive 56 days (8 weeks) that were RBC transfusion free during at least the 112 days (16 weeks) prior to Day 1 of the Pre-Randomization Phase.

This study was conducted in three phases:

  1. a Pre-Randomization Phase
  2. a Double-Blind Treatment Phase
  3. an Open-Label Extension Phase

Potentially protocol-eligible participants entered the Pre-Randomization Phase and were evaluated for the inclusion and exclusion criteria for the Double-Blind Treatment Phase. The Pre-Randomization Phase was not to last for more than 56 days (8 weeks). When the participant's baseline RBC transfusion requirement was calculated, and it had been determined that all eligibility criteria had been met, the participant could be randomized for treatment in the Double-Blind Treatment Phase at the time of their next RBC transfusion. This RBC transfusion had to occur within 56 days of the participant's last previous RBC transfusion.

Participants meeting eligibility criteria were randomized (1:1:1 ratio) to receive either lenalidomide 10 mg/day on days 1-21, lenalidomide 5 mg/day on days 1-28, or placebo on days 1-28; all on a 28-day cycle. Randomization was performed using a validated interactive voice response system. Participants were stratified according to karyotype (IPSS karyotype score: 0 vs > 0; i.e., isolated del 5q[31] vs del 5q[31] plus ≥ 1 additional cytogenetic abnormality). A complete blood count (CBC), serum or plasma ferritin, and EPO levels were measured to determine baseline levels.

Participants who achieved at least a minor erythroid response (i.e. 50% decrease in transfusion requirements) by week 16 could continue treatment in the Double-Blind phase for up to 52 weeks, unless there was evidence of erythroid relapse, disease progression, or unacceptable toxicity. Those who did not achieve at least a minor erythroid response by week 16 were discontinued from the Double-Blind phase for lack of therapeutic efficacy, and unblinded and were potentially eligible for Open-Label treatment. All participants who completed the double-blind treatment phase (the first 52 weeks of the trial) without disease progression or erythroid relapse were unblinded and entered the Open-Label extension phase at their current lenalidomide dose. Participants in the placebo or lenalidomide 5 mg arms who failed to achieve at least a minor erythroid response by week 16 or who had an erythroid relapse could cross over to lenalidomide 5 mg or 10 mg, respectively, in the Open-Label Extension phase.

Lenalidomide treatment could be continued in the Open-label Extension phase for up to 3 years (156 weeks) of total study participation. Participants with disease progression at any time and participants in the lenalidomide 10 mg group who did not achieve at least a minor erythroid response by week 16 were withdrawn from the study and were ineligible for Open-Label treatment.

Serial measurements for efficacy and safety were performed every 28 days. In addition, CBCs were monitored weekly for the first 8 weeks, every 2 weeks for the next 8 weeks, and every 4 weeks thereafter. Bone marrow aspirate (BMA) and standard cytogenetic studies were performed at baseline, weeks 12, week 24, and every 24 weeks thereafter and when clinically indicated for assessment of disease progression. BMAs were submitted for central pathology review and sent to a central cytogenetics laboratory for processing and review. All participants were followed for overall survival (OS) and progression to acute myeloid leukemia (AML).

Lenalidomide or placebo dosing was reduced for dose-limiting toxicities according to the following dose reduction schedule:

  • Lenalidomide 5 mg (starting dose)

    • dose level -1 (5 mg every other day)
    • dose level -2 (5 mg twice a week)
    • dose level -3 (5 mg weekly)
  • Lenalidomide 10 mg (starting dose)

    • dose level -1 (5 mg daily)
    • dose level -2 (5 mg every other day)
    • dose level -3 (5 mg twice a week)

Participants who could not tolerate dose level -3 discontinued treatment. For grade 4 neutropenia, lenalidomide was required per protocol to be interrupted and resumed at a decreased dose level when the absolute neutrophil count (ANC) recovered to ≥ 500/μL. For grade 4 thrombocytopenia, lenalidomide was interrupted and then resumed at a decreased dose level when the platelet count recovered to: between ≥ 25,000/μL and \< 50,000/μL on at least 2 occasions for ≥ 7 days; or ≥ 50,000 at any time, respectively. Prophylactic and therapeutic use of granulocyte colony-stimulating factors (G-CSF) or granulocyte macrophage colony-stimulating factors (GM-CSF) was allowed.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • MDS
  • transfusion dependent
  • anaemia
  • cytogenetic abnormality 5q-
  • erythroid response
  • leukaemia
  • CC-5013
  • Celgene
  • revlimid
  • lenalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must understand and voluntarily sign an form
  • Age 18 years at the time of signing the informed consent form
  • Documented diagnosis of myelodysplastic syndromes (MDS) that meets International Prognostic Scoring System (IPSS) criteria for low to intermediate-1-risk disease and has an associated del 5q(31) cytogenetic abnormality
  • Red blood cell (RBC) transfusion dependent anaemia defined as not having any 56 days without a RBC transfusion within at least the immediate 112 days
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Women of must have a negative pregnancy test prior to inclusion

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Prior therapy with lenalidomide
  • Proliferative (white blood cell (WBC)= 12,000/mL) chronic myelomonocytic leukemia (CMML)
  • Prior >= grade-2 (using the National Cancer Institute (NCI)'s Common Terminology Criteria for AEs () (v 3.0)) allergic reaction to thalidomide
  • Prior desquamating (blistering) rash while taking thalidomide
  • Prior history of other than MDS (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for >3 years
  • Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 28 days
  • Less than 6 months since prior bone marrow transplantation
  • Less than 3 months since prior autologous bone marrow or stem cell transplantation
  • Less than 28 days since prior myelosuppressive anticancer biologic therapy
  • Recombinant human erythropoietin (rHuEPO) therapy received within 28 days
  • Known (HIV-1) positivity
  • Any serious medical condition or psychiatric illness that will prevent the subject from signing the form or will place the subject at unacceptable risk if he or she participates in the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
205 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo matching to active study arms.

    Drug: Placebo

  • Experimental
    Lenalidomide 5 mg

    Lenalidomide 5 mg daily 28/28 days

    Drug: Lenalidomide 5 mg

  • Experimental
    Lenalidomide 10 mg

    Lenalidomide 10 mg daily 21/28 days

    Drug: Lenalidomide 10 mg

Interventions

  • Lenalidomide 5 mg daily 28/28 days

    Also known as: Revlimid

  • Lenalidomide 10 mg daily 21/28 days

    Also known as: Revlimid

  • DrugPlacebo

    Placebo, matching to active study drug arms

06

What researchers measure

Primary outcomes

  1. Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days)

    The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days

    Count of study participants who had no RBC transfusions during any 56 or more consecutive study days during the double-blind period.

    Time frame: Up to 52 weeks

  2. Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days

    Mean number of weeks that participants who achieved RBC transfusion independence for at least 182 days were able to maintain RBC transfusion independence. Both double-blind and open-label periods are included.

    Time frame: up to 3 years

  3. Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days

    For participants who became RBC transfusion independent for at least 182 days during the double-blind study period, the mean maximum change from baseline in hemoglobin is summarized.

    Time frame: Baseline, up to 52 weeks

  4. Participants' Response in Platelet Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period

    The International MDS Working Group (IWG) defines a major platelet response for participants with a pre-treatment platelet count of \<100,000/mm\^3 as an absolute increase of ≥30,000/mm\^3 whereas a minor response is defined as a ≥50% increase in platelet count with a net increase greater than 10,000/mm\^3 but less than 30,000/mm\^3.

    Time frame: up to 52 weeks

  5. Participants' Response in Absolute Neutrophil Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period

    A major neutrophil response is defined by the International MDS Working Group (IWG) criteria as at least a 100% increase, or an absolute increase of ≥500/mm\^3 for participants with absolute neutrophil counts (ANC) of less than 1,500/mm\^3 before therapy, whichever is greater. A minor response for such participants is defined as an ANC increase of at least 100%, but absolute increase \<500/mm\^3.

    Time frame: up to week 52

  6. Participants' Response Based on Bone Marrow Samples by the International MDS Working Group (IWG 2000) During Double-blind Period

    The IWG criteria for bone marrow improvement: a complete remission is bone marrow sampling showing less than 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. A partial remission is ≥ 50% decrease in blasts over pre-treatment. Bone marrow progression is a ≥ 50% increase in blasts that exceed the top range of the pretreatment percentile range: a) \<5% blasts b) 5-10% blasts c) 10-20% blasts d) 20-30% blasts. For example, a participant with \<5% blasts pretreatment with an on study blast increase of 50% which is now \>5% showed bone marrow progression.

    Time frame: up to 52 weeks

  7. Participants Showing Cytogenetic Response by the International MDS Working Group (IWG 2000) During Double-blind Period as Evaluated by Central Review

    The IWG criteria for evaluating cytogenetic response require a minimum of 20 baseline and post-baseline analyzable metaphases using conventional cytogenetic techniques. A major cytogenetic response is defined as no detectable cytogenetic abnormality if preexisting abnormality was present whereas a minor response requires ≥50% reduction in abnormal metaphases. Progression could be concluded based on as few as 3 metaphases if there were additional abnormalities. The best response is represented.

    Time frame: up to 52 weeks

  8. Participants Who Progressed to Acute Myeloid Leukemia (AML) During the Study

    Number of participants who progressed to acute myeloid leukemia during the study, summarized at three different timepoints: first 16 weeks of the double-blind study, week 52 of the double-blind study, and up to 36 months which includes the double-blind and open-label periods of the study. The counts are cumulative by timeframe.

    Time frame: up to 3 years

  9. Kaplan Meier Estimates of Overall Survival by Randomized Group

    Kaplan Meier estimate for median length of survival for study participants as they were randomized at the start of the study.

    Time frame: up to 3 years

  10. Participant Count of Deaths During Double-blind and Open-label by Randomized Group

    Count of participant deaths throughout the entire study and reported by the original treatment assignment.

    Time frame: up to 3 years

  11. Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12

    The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire (Yellen, 1997) was used to assess health-related quality of life (HRQoL). In addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning. The overall score range for the FACT-An is 0-188. Higher scores indicate better HRQoL.

    Time frame: Baseline, Week 12

  12. Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12

    The Trial Outcome Index-Anemia (TOI-An) composed of the physical and functional subscales of the FACT-G along with the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-An is 0-136. Higher scores indicate better HRQoL.

    Time frame: Baseline, Week 12

  13. Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12

    The Trial Outcome Index-Fatigue(TOI-F) composed of the physical and functional subscales of the FACT-G along with the fatigue items from the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-F is 0-108. Higher scores indicate better HRQoL.

    Time frame: Baseline, Week 12

  14. Summary of Participants Who Had Adverse Events (AE) During the Double-blind Period

    Counts of study participants who had adverse events (AEs) during the double-blind period by MedDRA System Organ Class (SOC) and preferred term. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.

    Time frame: up to week 52

07

Results

Posted Mar 17, 2011

Participant flow

Double-Blind Period
Participant flow — Double-Blind Period
MilestonePlaceboLenalidomide 5 mgLenalidomide 10 mgPlacebo Crossover to 5 mg Open-label Period
Started6769690
Completed323390
Not completed6446300
Withdrew: Lack of therapeutic effect5935190
Withdrew: Adverse event2740
Withdrew: Withdrawal by subject2130
Withdrew: Death0120
Withdrew: Protocol violation1000
Withdrew: Other0220
Open-Label Period
Participant flow — Open-Label Period
MilestonePlaceboLenalidomide 5 mgLenalidomide 10 mgPlacebo Crossover to 5 mg Open-label Period
Started0424756
Completed0141913
Not completed0282843
Withdrew: Lack of therapeutic effect0191931
Withdrew: Adverse event0656
Withdrew: Withdrawal by subject0222
Withdrew: Death0012
Withdrew: Other0112

Outcome measures

PrimaryParticipants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days)

The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.

Time frame:
Up to 52 weeks
Reported as:
Number · Participants
Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days)
ParticipantsPlaceboLenalidomide 5 mgLenalidomide 10 mg
Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days)32023
Statistical analysis
  • Placebo vs Lenalidomide 5 mg · Cochran-Mantel-Haenszel · p = <0.001 (To compare the response rates of Lenalidomide 5 mg QD vs. placebo, the Hochberg procedure was used to control the familywise error rate of 0.05.)Stratified by International Prognostic Scoring System (IPSS) score (IPSS combined score =0 versus \>0) to compare lenalidomide treatment with placebo.
  • Placebo vs Lenalidomide 10 mg · Cochran-Mantel-Haenszel · p = <0.001 (To compare the response rates of Lenalidomide 10 mg QD vs. placebo, the Hochberg procedure was used to control the familywise error rate of 0.05.)Stratified by International Prognostic Scoring System (IPSS) score (IPSS combined score =0 versus \>0) to compare lenalidomide treatment with placebo.
SecondaryParticipants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days

Count of study participants who had no RBC transfusions during any 56 or more consecutive study days during the double-blind period.

Time frame:
Up to 52 weeks
Reported as:
Number · Participants
Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days
ParticipantsPlaceboLenalidomide 5 mgLenalidomide 10 mg
Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days42425
Statistical analysis
  • Placebo vs Lenalidomide 5 mg · Cochran-Mantel-Haenszel · p = <0.001Stratified by International Prognostic Scoring System (IPSS) score (IPSS combined score =0 versus \>0) to compare lenalidomide treatment with placebo.
  • Placebo vs Lenalidomide 10 mg · Cochran-Mantel-Haenszel · p = <0.001Stratified by International Prognostic Scoring System (IPSS) score (IPSS combined score =0 versus \>0) to compare lenalidomide treatment with placebo.
SecondaryDuration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days

Mean number of weeks that participants who achieved RBC transfusion independence for at least 182 days were able to maintain RBC transfusion independence. Both double-blind and open-label periods are included.

Time frame:
up to 3 years
Reported as:
Mean · Weeks
Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days
WeeksPlaceboLenalidomide 5 mgLenalidomide 10 mg
Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days61.4 ± 10.93107.7 ± 52.35108.6 ± 40.63
SecondaryMaximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days

For participants who became RBC transfusion independent for at least 182 days during the double-blind study period, the mean maximum change from baseline in hemoglobin is summarized.

Time frame:
Baseline, up to 52 weeks
Reported as:
Mean · g/dL
Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days
g/dLPlaceboLenalidomide 5 mgLenalidomide 10 mg
Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days2.0 ± 0.615.5 ± 1.796.0 ± 1.97
SecondaryParticipants' Response in Platelet Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period

The International MDS Working Group (IWG) defines a major platelet response for participants with a pre-treatment platelet count of \<100,000/mm\^3 as an absolute increase of ≥30,000/mm\^3 whereas a minor response is defined as a ≥50% increase in platelet count with a net increase greater than 10,000/mm\^3 but less than 30,000/mm\^3.

Time frame:
up to 52 weeks
Reported as:
Number · Participants
Participants' Response in Platelet Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period
ParticipantsPlaceboLenalidomide 5 mgLenalidomide 10 mg
Major011
Minor000
None353
SecondaryParticipants' Response in Absolute Neutrophil Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period

A major neutrophil response is defined by the International MDS Working Group (IWG) criteria as at least a 100% increase, or an absolute increase of ≥500/mm\^3 for participants with absolute neutrophil counts (ANC) of less than 1,500/mm\^3 before therapy, whichever is greater. A minor response for such participants is defined as an ANC increase of at least 100%, but absolute increase \<500/mm\^3.

Time frame:
up to week 52
Reported as:
Number · Participants
Participants' Response in Absolute Neutrophil Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period
ParticipantsPlaceboLenalidomide 5 mgLenalidomide 10 mg
Major132
Minor001
None91514
SecondaryParticipants' Response Based on Bone Marrow Samples by the International MDS Working Group (IWG 2000) During Double-blind Period

The IWG criteria for bone marrow improvement: a complete remission is bone marrow sampling showing less than 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. A partial remission is ≥ 50% decrease in blasts over pre-treatment. Bone marrow progression is a ≥ 50% increase in blasts that exceed the top range of the pretreatment percentile range: a) \<5% blasts b) 5-10% blasts c) 10-20% blasts d) 20-30% blasts. For example, a participant with \<5% blasts pretreatment with an on study blast increase of 50% which is now \>5% showed bone marrow progression.

Time frame:
up to 52 weeks
Reported as:
Number · Participants
Participants' Response Based on Bone Marrow Samples by the International MDS Working Group (IWG 2000) During Double-blind Period
ParticipantsPlaceboLenalidomide 5 mgLenalidomide 10 mg
Complete remission0712
Partial remission051
Stable Disease373533
Progression343
SecondaryParticipants Showing Cytogenetic Response by the International MDS Working Group (IWG 2000) During Double-blind Period as Evaluated by Central Review

The IWG criteria for evaluating cytogenetic response require a minimum of 20 baseline and post-baseline analyzable metaphases using conventional cytogenetic techniques. A major cytogenetic response is defined as no detectable cytogenetic abnormality if preexisting abnormality was present whereas a minor response requires ≥50% reduction in abnormal metaphases. Progression could be concluded based on as few as 3 metaphases if there were additional abnormalities. The best response is represented.

Time frame:
up to 52 weeks
Reported as:
Number · Participants
Participants Showing Cytogenetic Response by the International MDS Working Group (IWG 2000) During Double-blind Period as Evaluated by Central Review
ParticipantsPlaceboLenalidomide 5 mgLenalidomide 10 mg
Major response0510
Minor response037
Cytogenetic progression5108
Not evaluable/data not available10101
SecondaryParticipants Who Progressed to Acute Myeloid Leukemia (AML) During the Study

Number of participants who progressed to acute myeloid leukemia during the study, summarized at three different timepoints: first 16 weeks of the double-blind study, week 52 of the double-blind study, and up to 36 months which includes the double-blind and open-label periods of the study. The counts are cumulative by timeframe.

Time frame:
up to 3 years
Reported as:
Number · Participants
Participants Who Progressed to Acute Myeloid Leukemia (AML) During the Study
ParticipantsPlaceboLenalidomide 5 mgLenalidomide 10 mg
Double-Blind (first 16 weeks)220
Double-Blind (52 weeks)472
Double-Blind + Open-Label211615
SecondaryKaplan Meier Estimates of Overall Survival by Randomized Group

Kaplan Meier estimate for median length of survival for study participants as they were randomized at the start of the study.

Time frame:
up to 3 years
Reported as:
Median · Months
Kaplan Meier Estimates of Overall Survival by Randomized Group
MonthsPlaceboLenalidomide 5 mgLenalidomide 10 mg
Kaplan Meier Estimates of Overall Survival by Randomized Group42.4 (31.9 to NA)NA (24.6 to NA)44.5 (35.5 to NA)
SecondaryParticipant Count of Deaths During Double-blind and Open-label by Randomized Group

Count of participant deaths throughout the entire study and reported by the original treatment assignment.

Time frame:
up to 3 years
Reported as:
Number · Participants
Participant Count of Deaths During Double-blind and Open-label by Randomized Group
ParticipantsPlaceboLenalidomide 5 mgLenalidomide 10 mg
Participant Count of Deaths During Double-blind and Open-label by Randomized Group353234
SecondaryChange From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12

The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire (Yellen, 1997) was used to assess health-related quality of life (HRQoL). In addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning. The overall score range for the FACT-An is 0-188. Higher scores indicate better HRQoL.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12
units on a scalePlaceboLenalidomide 5 mgLenalidomide 10 mg
Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12-2.5 ± 18.505.9 ± 18.265.8 ± 23.17
Statistical analysis
  • Placebo vs Lenalidomide 5 mg · ANOVA · p = <0.05
  • Placebo vs Lenalidomide 10 mg · ANOVA · p = <0.05
SecondaryChange From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12

The Trial Outcome Index-Anemia (TOI-An) composed of the physical and functional subscales of the FACT-G along with the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-An is 0-136. Higher scores indicate better HRQoL.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12
units on a scalePlaceboLenalidomide 5 mgLenalidomide 10 mg
Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12-1.1 ± 17.135.6 ± 15.564.9 ± 18.16
Statistical analysis
  • Placebo vs Lenalidomide 5 mg · ANOVA · p = 0.054
  • Placebo vs Lenalidomide 10 mg · ANOVA · p = 0.080
SecondaryChange From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12

The Trial Outcome Index-Fatigue(TOI-F) composed of the physical and functional subscales of the FACT-G along with the fatigue items from the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-F is 0-108. Higher scores indicate better HRQoL.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12
units on a scalePlaceboLenalidomide 5 mgLenalidomide 10 mg
Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12-0.8 ± 14.764.8 ± 14.213.9 ± 15.47
Statistical analysis
  • Placebo vs Lenalidomide 5 mg · ANOVA · p = 0.062
  • Placebo vs Lenalidomide 10 mg · ANOVA · p = 0.113
SecondarySummary of Participants Who Had Adverse Events (AE) During the Double-blind Period

Counts of study participants who had adverse events (AEs) during the double-blind period by MedDRA System Organ Class (SOC) and preferred term. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.

Time frame:
up to week 52
Reported as:
Number · participants
Summary of Participants Who Had Adverse Events (AE) During the Double-blind Period
participantsPlaceboLenalidomide 5 mgLenalidomide 10 mg
At least one AE646969
At least one AE related to study drug346866
At least one NCI CTCAE grade 3-4 AE296265
At least one related NCI CTCAE grade 3-4 AE136161
At least one serious AE143132
At least one serious AE related to study drug11713
An AE leading to discontinuation of study drug3126
An AE leading to dose reduction or interruption54451
Deaths within 30 days of last dose of study drug424

Adverse events

Collected over Placebo arm is limited to the double-blind period. Lenalidomide 5 mg and 10 mg treatment arms cover both double-blind and open-label periods. The Placebo Crossover to 5 mg Open-label Period arm is limited to the open-label period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—14/67 (20.9%)64/67 (95.5%)
Lenalidomide 5 mg—42/69 (60.9%)69/69 (100%)
Lenalidomide 10 mg—42/69 (60.9%)69/69 (100%)
Placebo Crossover to 5 mg Open-label Period—33/56 (58.9%)56/56 (100%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventPlaceboLenalidomide 5 mgLenalidomide 10 mgPlacebo Crossover to 5 mg Open-label Period
Acute Myeloid LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/678/698/695/56
NeutropeniaBlood and lymphatic system disorders0/675/695/695/56
ThrombocytopeniaBlood and lymphatic system disorders0/676/693/693/56
PyrexiaGeneral disorders2/675/692/693/56
PneumoniaInfections and infestations1/675/693/691/56
Deep Vein ThrombosisVascular disorders1/671/694/693/56
AnaemiaBlood and lymphatic system disorders0/674/691/691/56
Cardiac FailureCardiac disorders0/672/691/693/56
Febrile NeutropeniaBlood and lymphatic system disorders0/672/692/693/56
Urinary Tract InfectionInfections and infestations0/673/691/690/56
Most frequent other events
Showing 10 of 85
Most frequent other events
EventPlaceboLenalidomide 5 mgLenalidomide 10 mgPlacebo Crossover to 5 mg Open-label Period
NeutropeniaBlood and lymphatic system disorders12/6755/6957/6945/56
ThrombocytopeniaBlood and lymphatic system disorders2/6738/6936/6926/56
DiarrhoeaGastrointestinal disorders12/6732/6937/6926/56
NauseaGastrointestinal disorders6/6716/6921/6911/56
ConstipationGastrointestinal disorders5/6718/6919/6917/56
PruritusSkin and subcutaneous tissue disorders3/6716/6920/697/56
RashSkin and subcutaneous tissue disorders1/6718/6912/698/56
FatigueGeneral disorders5/6717/6917/6911/56
AnaemiaBlood and lymphatic system disorders6/6710/696/6913/56
Muscle SpasmsMusculoskeletal and connective tissue disorders6/6712/6915/6913/56

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboLenalidomide 5 mgLenalidomide 10 mgTotal
Median69.9 (39.0 to 85.0)66.0 (40.0 to 86.0)68.0 (36.0 to 84.0)68.0 (36.0 to 86.0)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLenalidomide 5 mgLenalidomide 10 mgTotal
Female545349156
Male13162049
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLenalidomide 5 mgLenalidomide 10 mgTotal
White666769202
Other1203
5q- (31-33) Chromosomal Abnormality
5q- (31-33) Chromosomal Abnormality(Participants)PlaceboLenalidomide 5 mgLenalidomide 10 mgTotal
Yes636464191
No1214
Missing33410
International Prognostic Scoring System (IPSS)
International Prognostic Scoring System (IPSS)(participants)PlaceboLenalidomide 5 mgLenalidomide 10 mgTotal
Low risk (0)30202070
Intermediate-1 (0.5 - 1.0)22292374
Intermediate-2 (1.5 - 2.0)25310
High Risk (≥ 2.5)0011
Missing data13152250
French-American-British (FAB) Classification
French-American-British (FAB) Classification(participants)PlaceboLenalidomide 5 mgLenalidomide 10 mgTotal
Refractory anemia (RA)373832107
Refractory anemia with ringed sideroblasts (RARS)87924
Refractory anemia with excess blasts (RAEB)49922
Chronic myelomonocytic leukemia (CMML)1203
RAEB in transformation1001
Chronic myelogenous leukemia (CML)0011
Specimen not adequate from diagnosis12111740
Other or missing4217
08

Study locations

38 sites
  • AZ St-Jan Brugge AV
    Brugge, 8000, Belgium
  • UZ Gent
    Gent, 900, Belgium
  • UZ Gasthuisberg
    Leuven, 3000, Belgium
  • CHU Mont Godine
    Yvoir, 5530, Belgium
  • Institut Paoli-Calmettes
    Marseille, Cedex 9 B.P.156 - 13272, France
  • CHU d'Angers Service des Maladies du Sang
    Angers, 49933, France
  • Hopital Avicenne
    Bobigny Cedex, France
  • CHRU Lille Service des Maladies du Sang
    Lille, 59037, France
  • CHU Nantes Hematologie et Medicine interne
    Nantes, 44093, France
  • CHU Archet 1Hematologie Clinique
    Nice, 06202, France
  • Hôpital Cochin Hematologie Clinique
    Paris, 75014, France
  • Centre Jean Bernhard Service Onco-Hematologie
    Poitiers, 86021, France
  • Centre Henri Becquerel Service d'Hematologie Clinique
    Rouen, 76038, France
  • CHU Purpan, Place du Dr Baylac, Pavillon des Médecines
    Toulouse, 31059, France
  • CHU Purpan, Place du Dr. Baylac, Pavillion des Medecines
    Toulouse, 31059, France
  • CHU Nancy Hematologie et Medecine interne
    Vandoeuvre, 54511, France
  • Universitaetsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • St Johannes Hospital
    Duisburg, 47166, Germany
  • Universitaetsklinikum Freiburg
    Freiburg, 79106, Germany
  • Hannover Medical School
    Hannover, D-30625, Germany
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Ospedale Niguarda Ca Granda
    Milano, 20162, Italy
  • University of Pavia Division of Hematology
    Pavia, 27100, Italy
  • University of Medical Centre
    Nijmegen, 6526 GA, Netherlands
  • Hematologie Erasmus MC
    Rotterdam, 3000CA, Netherlands
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario La Fe
    Valencia, 46009, Spain
  • SU/Sahlgrenska Section of Hematology & Coagulation
    Goteborg, SE 413 45, Sweden
  • Department of Medicine University Hospital
    Lund, S-221 85, Sweden
  • Korolinska Institutet Department of Hematology
    Stockholm, 14186, Sweden
  • University Hospital of Wales, Dept of Haematology
    Cardiff, Wales CF14 4XW, United Kingdom
  • Leed General Infirmary
    Leeds, West Yorkshire LS1 3 EX, United Kingdom
  • The Royal Bournemouth Hospital
    Bournemouth, BH7 7DW, United Kingdom
  • Ninewells Hospital and Medical School
    Dundee, DD1 9SY, United Kingdom
  • Kings College Hospital, Denmark Hill
    London, SE 5 9RS, United Kingdom
  • Central Manchester and Manchester Children's University Hospitals NHS Trust
    Manchester, M13 9WL, United Kingdom
  • Nottingham City Hospital
    Nottingham, NG5 1PB, United Kingdom
  • John Radcliffe Hospital and the Weatherall Institute of Molecular Medicine
    Oxford, OX3 9DS, United Kingdom
09

References and documents

Publications

  • Fenaux, Pierre, Giagounidis, Aristotle, Selleslag, Dominik, Beyne-Rauzy, Odile, Mufti, Ghulam J, Mittelman, Moshe, Muus, Petra, te Boekhorst, Peter, Sanz, Guillermo, del Canizo, Consuelo, Guerci-Bresler, Agnes, Schlegelberger, Brigitte, Aul, Carlo, Kreipe, Hans, Goehring, Gudrun, Knight, Robert, Francis, John, Fu, Tommy, Hellstrom-Lindberg, Eva. RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004). ASH Annual Meeting Abstracts 2009 114: 944.
  • Fenaux, P., Giagounidis, A., Selleslag, D. L., Beyne-Rauzy, O., Mittelman, M., Muus, P., Knight, R. D., Fu, T., Hellstrom-Lindberg, E., The MDS-004 Len del(5q) Study Group. Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. J Clin Oncol (Meeting Abstracts) 2010 28: 6598
  • Fenaux, P., Giagounidis, A., Selleslag, D., Knight, R., Fu, T., Hellström-Lindberg, E. Effect of baseline EPO and prior erythropoiesis stimulating agents on RBC transfusion independence in Low-/Int-1-Risk MDS with del 5q treated with lenalidomide: A randomized phase 3 study (MDS-004). Haematologica 2010; 95[suppl.2]:125, abs. 0311.
  • Brandenburg, N., Fu, T., Revicki, D., Knight, R., Muus, P., Fenaux, P. Impact of lenalidomide on health-related quality of life in patients with RBC transfusion-dependent low- or int-1-risk myelodysplastic syndromes with del 5q: a randomized Phase 3 study (MDS-004). Haematologica 2010; 95[suppl.2]:127, abs. 0316
  • Fenaux, P., Giagounidis, A., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., te Boekhorst, P., Sanz, G., Cazzola, M., Backstrom, J., Fu, T., Hellström-Lindberg, E. Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004). Blood ASH Annual Meeting Abstracts 2010 116:21 abs. 4027.
  • Brandenburg, N., Yu, R., Revicki, D. Reliability and Validity of the FACT-AN In Patients with Low or Int-1-Risk Myelodysplastic Syndromes with Deletion 5q. Blood ASH Annual Meeting Abstracts 2010 116:21 abs. 3827.
  • Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellstrom-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Canizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2. PubMed 28651604 ↗
  • Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Gohring G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, Fenaux P, MacBeth KJ, Hellstrom-Lindberg E. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014 Jun;99(6):1041-9. doi: 10.3324/haematol.2013.098103. Epub 2014 Mar 28. PubMed 24682512 ↗
  • Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Canizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lubbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellstrom-Lindberg E; MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13. PubMed 21753188 ↗
  • Gohring G, Giagounidis A, Busche G, Hofmann W, Kreipe HH, Fenaux P, Hellstrom-Lindberg E, Schlegelberger B. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide. Haematologica. 2011 Feb;96(2):319-22. doi: 10.3324/haematol.2010.026658. Epub 2010 Nov 25. PubMed 21109690 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Jun 2008 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2005
First posted
Sep 16, 2005
Start
Jul 2005
Primary completionActual
Jun 2008
CompletionActual
Jun 2010
Results first posted
Mar 17, 2011
Last update
Apr 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00179621
Collaborators
ICON Clinical Research
First posted
Sep 16, 2005
Start date
Jul 2005
Primary completion
Jun 2008
Completion
Jun 2010
Results posted
Mar 17, 2011
Last update
Apr 14, 2011

Study contacts

Jay Backstrom, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion